PRINCETON, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David Mack, Ph.D., President and Chief Executive Officer of PMV Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference taking place in Boston, Massachusetts March 4-6, 2024.
The company will also be available to meet one-on-one with institutional investors at the conference. Details about the fireside chat can be found below.
| TD Cowen 44th Annual Health Care Conference | |
| Date: | Monday, March 4, 2024 |
| Time: | 2:50 – 3:20 PM ET |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. p53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Kathy Vincent
Greig Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.26 |
| Daily Change: | -0.03 -2.33 |
| Daily Volume: | 1,099,253 |
| Market Cap: | US$67.040M |
November 12, 2025 September 10, 2025 August 07, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
